| Document |
Document Title |
|
WO/2008/040979A1 |
The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
|
|
WO/2008/039162A1 |
The invention relates to polyguanidine synthesis. The inventive method for producing polyguanidines consists in polycondensing a guanidine salt with diamine during heating in the presence of an organic acid or a mixture of organic acids....
|
|
WO/2008/031212A1 |
The present invention relates to a conjugated salt of creatine and pyroglutamic acid The salt is water soluble and stable and can be used for the regulation of athletic and cognitive functions in a mammal The invention also discloses a p...
|
|
WO/2008/033365A2 |
A free amino ion releasing molecule useful for a wide variety of medical and cosmetic applications. The chemical name of the new molecule in acetate form name is 2- amino 5-triaminoguanidovalericbenzoicdiacetate, sometime referred to her...
|
|
WO/2008/031199A1 |
There are provided compounds of formulas (I) and (II): Various chemical entities can be used for R1 to R6. These compounds comprise at least one polymerizable entity. These compounds can be useful for preparing various polymers. The poly...
|
|
WO/2008/031456A1 |
The present invention is directed to a process for preparing hexamethylenebiscyanoguanidine. This compound is used as an intermediate to prepare chlorhexidine. The formation of the hexamethylenebiscyanoguanidine proceeds under base catal...
|
|
WO/2008/029810A1 |
Disclosed is a pest control agent having a high, stable pest control effect. Specifically disclosed is a phenylguanidine derivative represented by the formula (I) below or a salt thereof. (In the formula, R1 represents a hydrogen, an alk...
|
|
WO/2008/026757A1 |
The present invention provides a process for producing 1-(3,4-dichlorobenzyl)-5-octylbiguanide or a salt thereof, the process comprising reacting 1-cyano-3-octylguanidine or a salt thereof, with 3,4-dichlorobenzylamine or a salt thereof,...
|
|
WO/2008/019594A1 |
Agmatine sulfate dihydrate represented by formula (I), its crystal form and pharmaceutical composition, use for treating drug abuse, antiinflammatory, lowering blood glucose levels and prevention and/or treatment of diseases caused by ag...
|
|
WO/2008/015240A1 |
The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinso...
|
|
WO/2008/013555A1 |
Purification materials with broad spectrum antimicrobial properties and methods and devices for fluid treatment utilizing said materials are provided. The purification materials include biguanide hydrates and bases. A particular composit...
|
|
WO/2007/147252A1 |
The present invention provides the use of prodrugs of pelorol and homopelorol, related compounds and pharmaceutical compositions thereof as modulators of SHIPl activity. A compound or a pharmaceutical composition of the present invention...
|
|
WO/2007/143880A1 |
Compounds having general structural formula (I) and their pharmaceutically acceptable salts, wherein n = 0 or 1; R = H, C1-6 alkyl, or C6-12 aryl; X = O or NH; and Y is absent, carbonyl, or NH. The compound are prepared from two correspo...
|
|
WO/2007/146086A1 |
Membrane permeable prodrugs of creatine, pharmaceutical compositions comprising membrane permeable prodrugs of creatine, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising adminis...
|
|
WO/2007/137107A2 |
The present invention relates to compounds of formula (I) wherein R1, R3, X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.
|
|
WO/2007/129952A1 |
The invention relates to a compound having the general formula (I) R1-NH-CH[(CH2)n-NH-C(NH)-NH2]-CO-R2-A-R4; a pharmaceutical composition comprising said compound and use of said compound for the manufacturing of a medicament for the tre...
|
|
WO/2007/118589A1 |
Disclosed are compounds of formula (I) and the salts thereof, wherein R1represents a radical of formula -N(B1-D1)(B2-D2) or -N(B3-D3)-N(B4-D4)(B5-D5), or a group of formula (II) or (III), B1, B2, B3, B4, B5, D1, D2, D3, D4, D5, G1, L1, U...
|
|
WO/2007/115799A1 |
A process is proposed for preparing creatine, creatine monohydrate or guanidinoacetic acid, wherein N-methylethanolamine or ethanolamine is first catalytically dehydrogenated, in each case in alkaline solution, and the sarcosinate or gly...
|
|
WO/2007/099934A1 |
A combination of aliphatic amino acids labeled with stable isotope for realizing of an analysis of the conformation of protein of high molecular weight, especially molecular weight as high as exceeding 60 kDa. There is provided a combina...
|
|
WO/2007/095050A2 |
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods for the treatment of IDO-associated diseases.
|
|
WO/2007/079506A1 |
The invention relates to the frequency conversion of the laser radiation and the field of preparation of nonlinear optical materials usable in laser technology for electro-optical modulation. The crystalline triclinic form of L-nitroargi...
|
|
WO/2007/066460A1 |
The object is to provide a technique for forming a selective metal coating film on a non-conductive resin by allowing a catalyst metal to adsorb selectively onto an anionic group (e.g., a carboxyl group) on the resin. Thus, disclosed are...
|
|
WO/2007/045572A1 |
The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5 and X are as herein de...
|
|
WO/2007/034924A1 |
Disclosed is a metallo-β-lactamase inhibitor which can inactivate a β-lactam antibiotic and recover the anti-bacterial activity of the β-lactam antibiotic. A maleic acid derivative having a structure of the general formula (I) has an ...
|
|
WO/2007/029587A1 |
Disclosed is a compound represented by the formula (1) below which is useful as a drug for treating Alzheimer's disease, or a pharmaceutically acceptable salt thereof. (1) [In the formula, R1 represents a group represented by the followi...
|
|
WO/2007/021839A2 |
Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.
|
|
WO/2006/136846A1 |
The invention provides a compound of formula (I); or a salt or solvate thereof, wherein: R1 is hydrogen or C1-4alkyl; R2 and R4 are each independently selected from C1-4 alkyl, [11C] C1 4alkyl, and [18F]-C1-4 fluoroalkyl provided that at...
|
|
WO/2006/135978A1 |
The present invention relates to novel compounds and compositions having antiviral activity. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals.
|
|
WO/2006/118283A1 |
Disclosed are guanidine compounds represented by the formula (1) below and salts thereof. Also disclosed is a bactericidal composition containing any of such guanidine compounds and salts thereof. [Chemical formula 1] (1) [In the formula...
|
|
WO/2006/108643A1 |
The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory disea...
|
|
WO/2006/108643A2 |
The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory disea...
|
|
WO/2006/097015A1 |
Agmatines labeled by deuterium and tritium and their preparation methods are disclosed. The uses of said compounds and related intermediates in the research of biochemical mechanism and medicines are also described.
|
|
WO/2006/088705A1 |
ABSTRACT OF THE INVENTION The present invention provides terphenyl guanidine compounds of formula I. The present invention also provides methods for the use thereof to inhibit ß-secretase (BACE) and treat ß-amyloid deposits and neurofi...
|
|
WO/2006/081682A1 |
Methods of production for Tricreatine Hydroxycitrate are disclosed. Tricreatine hydroxycitrate can be used as supplemental dietary ingredient for the purposes of reducing adiposity, suppression of appetite, improvement of muscle and exer...
|
|
WO/2006/074501A1 |
The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in...
|
|
WO/2006/066894A1 |
Compounds of general formula (I), wherein R’, R, x and z have the meaning reported in the specification, are useful for treating inflammatory diseases including metabolic syndrome, diabetes, obesity, dyslipidemia, and insulin resistance.
|
|
WO/2006/063656A1 |
The invention relates to a method for producing onium salts comprising alkyl anions or aryl sulfonate anions or alkyl carboxylate anions or acryl carboxylate anions by reacting an onium halide with an alkyl silyl ester or trialkyl silyl ...
|
|
WO/2006/063653A1 |
The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.
|
|
WO/2006/063654A1 |
The invention relates to a method for producing onium alkyl sulfates by reacting an onium halogenide with a symmetrically substituted dialkyl sulfate, the alkyl group thereof containing between 1 and 14 C atoms, with an unsymmetrically s...
|
|
WO/2006/051314A2 |
Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for ...
|
|
WO/2006/044707A1 |
This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
|
|
WO/2006/023586A2 |
The present invention relates to compounds having the formula I: salts thereof; compositions comprising one or more of the compounds and/or salts thereof; methods of using; and methods of making.
|
|
WO/2006/010422A1 |
Compounds of the formula (I) in which the radicals R and R1 to R10 are as defined in the description, processes for the preparation of them, use thereof for the treatment of cardiovascular diseases, and pharmaceutical compositions compri...
|
|
WO/2006/004613A2 |
The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their...
|
|
WO/2006/000756A1 |
A sanitizing composition capable of destroying pathogens present at a locus and/or of removing biofilm present at a locus (for example MRSA or Legionella) aqueous solution: at least one surfactant, preferably non-ionic; at least one anti...
|
|
WO/2005/123646A2 |
The production of fluoroorganic compounds in the form of amidoamines, quaternised compounds thereof, amides and ethers, guanidides, hydrazides, ureides, thioureides, perfluoropolyoxaalkylenesulfo- or perfluoropolyoxaalkylenecarboxylic ac...
|
|
WO/2005/123660A2 |
Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present inventio...
|
|
WO/2005/123676A1 |
The invention relates to compounds of formula: I, or pharmaceutically acceptable a salts thereof, I wherein X1 X2 and X3 are each independently where Y is an alkylene, alkenylene or alkynylene group, each of which may be optionally subst...
|
|
WO/2005/123700A1 |
The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atheroscleros...
|
|
WO/2005/105152A2 |
The present invention is related to a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group compr...
|
